Phase 2b/3 PRISM Upcoming Data is Trevi's (TRVI) Most Important Readout, Maintain Buy Into the Analysis - Needham & Company
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $8.00 price target on Trevi Therapeutics (NASDAQ: TRVI), following ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
